Harwood Feffer LLP Announces Investigation of Keryx Biopharmaceuticals, Inc.

NEW YORK, Feb. 8, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NASDAQ: KERX), concerning whether the board has breached its fiduciary duties to shareholders.

(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )

On April 2, 2012, the Company disclosed that the Phase 3 Clinical Trial did not meet the primary endpoint of improving patient survival when compared to another drug and a placebo.  On this news, the Company's shares lost more than 60% of their value over two trading days.   

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own Keryx shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq. 
Matthew M. Houston, Esq. 
Benjamin I. Sachs-Michaels, Esq. 
Harwood Feffer LLP 
488 Madison Avenue 
New York, New York 10022 
Phone Numbers: (877) 935-7400
                           (212)935-7400
Email:  bsachsmichaels@hfesq.com
Website:   http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

SOURCE Harwood Feffer LLP